{"id":"placebo-to-veliparib","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL506871","moleculeType":"Small molecule","molecularWeight":"244.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PARP enzymes are involved in single-strand DNA break repair. By inhibiting PARP, veliparib prevents cancer cells from repairing DNA damage, leading to accumulation of DNA lesions and cell death. This is particularly effective in tumors with BRCA mutations or homologous recombination deficiency, which rely heavily on PARP-mediated repair pathways.","oneSentence":"Veliparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and causing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:03.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer (in combination with chemotherapy)"},{"name":"Ovarian cancer"},{"name":"BRCA-mutated cancers"}]},"trialDetails":[{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT02163694","phase":"PHASE3","title":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-08","conditions":"Metastatic Breast Cancer","enrollment":513},{"nctId":"NCT02470585","phase":"PHASE3","title":"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07-14","conditions":"Ovarian Cancer, Ovarian Neoplasm","enrollment":1140},{"nctId":"NCT01711541","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10-22","conditions":"Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7","enrollment":24},{"nctId":"NCT01506609","phase":"PHASE2","title":"Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2012-01-23","conditions":"Metastatic Breast Cancer","enrollment":294},{"nctId":"NCT02032277","phase":"PHASE3","title":"A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-02","conditions":"Triple Negative Breast Cancer","enrollment":634},{"nctId":"NCT02106546","phase":"PHASE3","title":"Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-10","conditions":"Squamous Non-Small Cell Lung Cancer","enrollment":970},{"nctId":"NCT02412371","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-04-30","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":48},{"nctId":"NCT02289690","phase":"PHASE1, PHASE2","title":"Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Small Cell Lung Cancer","enrollment":221},{"nctId":"NCT02305758","phase":"PHASE2","title":"Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-02","conditions":"Untreated Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT01657799","phase":"PHASE2","title":"Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10-19","conditions":"Brain Metastases From Non-small Cell Lung Cancer","enrollment":307},{"nctId":"NCT02009631","phase":"PHASE1","title":"A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Breast Cancer, Ovarian Cancer, Colon Cancer","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to veliparib","genericName":"Placebo to veliparib","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Veliparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and causing cancer cell death. Used for Metastatic breast cancer (in combination with chemotherapy), Ovarian cancer, BRCA-mutated cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}